Smart Medication ™, an Electronic Diary for Surveillance of Haemophilia Home Care and Optimization of Resource Distribution
Standard
Smart Medication ™, an Electronic Diary for Surveillance of Haemophilia Home Care and Optimization of Resource Distribution. / Mondorf, Wolfgang; Eichler, Hermann; Fischer, Ronald; Holstein, Katharina; Klamroth, Robert; Nimtz-Talaska, Antje; Wermes, Cornelia; Richter, Heinrich; Severin, Kai.
In: HAMOSTASEOLOGIE, Vol. 39, No. 4, 11.2019, p. 339-346.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Smart Medication ™, an Electronic Diary for Surveillance of Haemophilia Home Care and Optimization of Resource Distribution
AU - Mondorf, Wolfgang
AU - Eichler, Hermann
AU - Fischer, Ronald
AU - Holstein, Katharina
AU - Klamroth, Robert
AU - Nimtz-Talaska, Antje
AU - Wermes, Cornelia
AU - Richter, Heinrich
AU - Severin, Kai
N1 - Georg Thieme Verlag KG Stuttgart · New York.
PY - 2019/11
Y1 - 2019/11
N2 - This report describes the technical features and potential advantages of the application of electronic haemophilia treatment diary smart medication™ and an evaluation of real-life electronic treatment data collected from haemophilia patients. Since 2012, a total of 663 patients from 30 German haemophilia treatment centres (HTCs) have used the device. Data of nine HTCs were merged for real-life data analysis. Patients were divided into four subgroups according to above versus below mean values for annual factor consumption (AFC) and annual joint bleeds (AJB), respectively. The largest subgroup comprised patients with low mean AFC and AJB less than 2.25 (group A: 42%). Second largest was the group with low mean AJB but high AFC (group B: 32%), suggesting that resources could be saved in some patients. The group with low AFC but high AJB may need increased factor dosing (group D: 13%). Patients who showed a high mean AJB despite high AFC (group C: 13%) may require special medical attention, such as pharmacokinetic-adapted treatment modification or orthopaedic measures. Smart medication™ enables the HTC to quickly identify patients in need of treatment changes and, thus, to plan individualized therapy modifications prior to patient visits. The growing pool of real-life data facilitates data analysis and may play an important role in the optimization of resource distribution.
AB - This report describes the technical features and potential advantages of the application of electronic haemophilia treatment diary smart medication™ and an evaluation of real-life electronic treatment data collected from haemophilia patients. Since 2012, a total of 663 patients from 30 German haemophilia treatment centres (HTCs) have used the device. Data of nine HTCs were merged for real-life data analysis. Patients were divided into four subgroups according to above versus below mean values for annual factor consumption (AFC) and annual joint bleeds (AJB), respectively. The largest subgroup comprised patients with low mean AFC and AJB less than 2.25 (group A: 42%). Second largest was the group with low mean AJB but high AFC (group B: 32%), suggesting that resources could be saved in some patients. The group with low AFC but high AJB may need increased factor dosing (group D: 13%). Patients who showed a high mean AJB despite high AFC (group C: 13%) may require special medical attention, such as pharmacokinetic-adapted treatment modification or orthopaedic measures. Smart medication™ enables the HTC to quickly identify patients in need of treatment changes and, thus, to plan individualized therapy modifications prior to patient visits. The growing pool of real-life data facilitates data analysis and may play an important role in the optimization of resource distribution.
U2 - 10.1055/s-0038-1675575
DO - 10.1055/s-0038-1675575
M3 - SCORING: Journal article
C2 - 30620988
VL - 39
SP - 339
EP - 346
JO - HAMOSTASEOLOGIE
JF - HAMOSTASEOLOGIE
SN - 0720-9355
IS - 4
ER -
